PanTher Therapeutics
PanTher Therapeutics is a biotechnology company based in Austin, Texas, focused on developing innovative cancer treatments. Its lead product candidate, PTM-101, is in clinical development for pancreatic cancer, utilizing the proprietary Sagittari platform to enhance drug delivery and efficacy.
Company Overview
PanTher Therapeutics is a biotechnology company founded in 2016, headquartered in Austin, Texas, with a location in Watertown, Massachusetts. The company operates as a small business with a team size of 17. PanTher Therapeutics focuses on developing innovative cancer treatments, leveraging proprietary technology to optimize drug delivery and efficacy.
Lead Product Candidate
The lead product candidate of PanTher Therapeutics is PTM-101, which is currently in ongoing clinical development for the treatment of pancreatic cancer. PTM-101 has successfully completed a Phase 1 clinical trial, demonstrating a local response and an excellent safety profile. The treatment aims to provide a significant increase in drug concentration at the tumor site while minimizing systemic exposure.
Technology Platform
PanTher Therapeutics utilizes the Sagittari™ platform, a polymer-based system invented at the Massachusetts Institute of Technology. This proprietary technology enables the formulation of therapeutic agents in various dosage forms. The platform allows for tailored dosing, continuous release of drugs at the tumor site, and adaptation to different drug modalities, including mRNA and proteins.
Funding and Support
PanTher Therapeutics has received significant funding to advance its cancer treatment initiatives. The company was awarded $14.2 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the development of targeted, localized, and sustained cancer therapies. Additionally, the company has obtained FDA clearance for its Investigational New Drug (IND) application for a Phase 1b study of PTM-101.
Clinical Applications
The Sagittari platform has potential applications across various cancer indications, including pancreatic, colon, and lung cancers. The technology enables high-dose treatment localized to the tumor site, which can be tailored based on tumor location and patient needs. This approach aims to improve tolerability and effectiveness in cancer treatment.